Rhythm Pharmaceuticals (RYTM) News Today $60.14 +0.59 (+0.99%) As of 03:21 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period JPMorgan Chase & Co. Raises Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)JPMorgan Chase & Co. lifted its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 224.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 264,585 shares of the company's stock after acquiringApril 14 at 3:29 AM | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Down 8% - Here's What HappenedRhythm Pharmaceuticals (NASDAQ:RYTM) Trading Down 8% - Here's WhyApril 11 at 12:34 PM | marketbeat.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Sells 17,750 Shares of StockApril 11 at 5:30 AM | insidertrades.comRhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $92.00April 11 at 4:17 AM | americanbankingnews.comRhythm Pharmaceuticals' (RYTM) "Buy" Rating Reiterated at Needham & Company LLCApril 11 at 4:17 AM | americanbankingnews.comRhythm Pharmaceuticals price target raised to $68 from $63 at BofAApril 11 at 12:25 AM | markets.businessinsider.comRhythm Pharmaceuticals (NASDAQ:RYTM) Trading Up 11.9% After Analyst UpgradeRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Up 11.9% After Analyst UpgradeApril 10, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and set a $66.00 target price on shares of Rhythm Pharmaceuticals in a report on Tuesday.April 10, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Expected to Rise, Canaccord Genuity Group Analyst SaysCanaccord Genuity Group lifted their target price on shares of Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the company a "buy" rating in a report on Tuesday.April 10, 2025 | marketbeat.comRhythm Pharmaceuticals' (RYTM) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $80.00 price target (up from $70.00) on shares of Rhythm Pharmaceuticals in a report on Tuesday.April 10, 2025 | marketbeat.comAmerican Century Companies Inc. Makes New Investment in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)American Century Companies Inc. acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 33,766 shares of the company's stock, valued atApril 10, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Trading 11.9% Higher After Analyst UpgradeApril 10, 2025 | americanbankingnews.comRhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up on Analyst UpgradeRhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Up Following Analyst UpgradeApril 9, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $91.00 at Wells Fargo & CompanyWells Fargo & Company boosted their price objective on shares of Rhythm Pharmaceuticals from $80.00 to $91.00 and gave the stock an "overweight" rating in a research note on Monday.April 9, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Rating Upgraded by Bank of AmericaBank of America upgraded Rhythm Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $63.00 price objective on the stock in a research note on Monday.April 9, 2025 | marketbeat.comADAR1 Capital Management LLC Takes $1.73 Million Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)ADAR1 Capital Management LLC bought a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 30,941 shares of tApril 9, 2025 | marketbeat.comFederated Hermes Inc. Decreases Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Federated Hermes Inc. lessened its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 6.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,549,635 shares of the company's stock after selling 114,265 shareApril 9, 2025 | marketbeat.comGuggenheim Sticks to Its Buy Rating for Rhythm Pharmaceuticals (RYTM)April 9, 2025 | markets.businessinsider.comFranklin Resources Inc. Has $15.01 Million Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Franklin Resources Inc. lifted its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 3.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 268,205 shares of the company's stockApril 9, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Rhythm Pharmaceuticals (NASDAQ:RYTM)April 9, 2025 | americanbankingnews.comNorges Bank Acquires New Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Norges Bank bought a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 205,649 shares of the company's stApril 9, 2025 | marketbeat.comWells Fargo & Company Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock PriceApril 9, 2025 | americanbankingnews.comRhythm jumps after late-stage trial win; BofA upgrades (update)April 8, 2025 | msn.comRhythm Pharmaceuticals Stock Rises On Positive Trial Data From Therapy In Treating Hypothalamic Obesity: Retail, Analysts Get More BullishApril 8, 2025 | msn.comRhythm Pharmaceuticals price target raised to $92 from $81 at CanaccordApril 8, 2025 | markets.businessinsider.comRhythm Pharmaceuticals stock rises on trial successApril 7, 2025 | investing.comRhythm Pharmaceuticals Weight Loss Drug Study Shows Significant BMI Reduction For Rare Type Of Obesity DisorderApril 7, 2025 | finance.yahoo.comRhythm posts late-stage trial win for lead asset against rare form of obesityApril 7, 2025 | msn.comRhythm Pharmaceuticals' drug for rare obesity disorder meets main goal in late-stage trialApril 7, 2025 | reuters.comRhythm Pharmaceuticals Announces Pivotal Phase 3 TRANSCEND Trial Meets Primary Endpoint with -19.8% Placebo-adjusted BMI Reduction in Patients (N=120) with Acquired Hypothalamic ObesityApril 7, 2025 | globenewswire.comRhythm Pharmaceuticals to Announce Topline Results from Pivotal Phase 3 TRANSCEND Trial Evaluating Setmelanotide in Patients with Acquired Hypothalamic ObesityApril 6, 2025 | globenewswire.com82,755 Shares in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Purchased by Cinctive Capital Management LPCinctive Capital Management LP acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 82,755 shares of the companyApril 5, 2025 | marketbeat.comBryce Point Capital LLC Invests $1.10 Million in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Bryce Point Capital LLC bought a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 19,607 shares of the companApril 5, 2025 | marketbeat.comKLP Kapitalforvaltning AS Acquires Shares of 9,300 Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)KLP Kapitalforvaltning AS acquired a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 9,300 shares of the company's stock, vaApril 5, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Bought by Pictet Asset Management Holding SAPictet Asset Management Holding SA increased its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 14.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 375,349 shares of the coApril 2, 2025 | marketbeat.comRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Receives Average Recommendation of "Moderate Buy" from BrokeragesRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) has earned an average recommendation of "Moderate Buy" from the thirteen brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and twelve have given a buy raMarch 30, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Up 2.4% - What's Next?Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Up 2.4% - Here's What HappenedMarch 29, 2025 | marketbeat.comLoomis Sayles & Co. L P Sells 18,143 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Loomis Sayles & Co. L P decreased its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) by 2.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 618,485 shares of the company's stock after selling 18,143 sharMarch 29, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Soleno Therapeutics (SLNO) and Rhythm Pharmaceuticals (RYTM)March 27, 2025 | markets.businessinsider.comQ1 EPS Forecast for Rhythm Pharmaceuticals Cut by AnalystRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Research analysts at HC Wainwright cut their Q1 2025 earnings estimates for Rhythm Pharmaceuticals in a note issued to investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings oMarch 27, 2025 | marketbeat.comQ2 Earnings Estimate for RYTM Issued By HC WainwrightRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) - Stock analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for shares of Rhythm Pharmaceuticals in a research note issued to investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju forecasts that the comMarch 26, 2025 | marketbeat.comCibc World Markets Corp Purchases New Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Cibc World Markets Corp acquired a new position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 5,123 shares of the company's stock, valued at approximately $287,000. Several otherMarch 26, 2025 | marketbeat.comInsider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) CAO Sells 344 Shares of StockRhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) CAO Christopher Paul German sold 344 shares of the stock in a transaction that occurred on Friday, March 21st. The shares were sold at an average price of $54.23, for a total transaction of $18,655.12. Following the completion of the transaction, the chief accounting officer now directly owns 2,889 shares of the company's stock, valued at $156,670.47. The trade was a 10.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.March 25, 2025 | marketbeat.comRhythm Pharmaceuticals (NASDAQ:RYTM) Receives "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $70.00 price objective on shares of Rhythm Pharmaceuticals in a report on Monday.March 25, 2025 | marketbeat.com7RYTM : Analyst Expectations For Rhythm Pharmaceuticals&#...March 24, 2025 | benzinga.comConnor Clark & Lunn Investment Management Ltd. Buys New Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,089March 24, 2025 | marketbeat.comRhythm Pharmaceuticals receives orphan drug status in JapanMarch 21, 2025 | investing.comRhythm Pharmaceuticals reacquires rights to Imcivree in China for $6.3MMarch 21, 2025 | markets.businessinsider.comIs Rhythm Pharmaceuticals (RYTM) a Worst High-Risk High-Reward Growth Stock to Buy?March 21, 2025 | msn.comRhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.March 20, 2025 | globenewswire.com Remove Ads Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address RYTM Media Mentions By Week RYTM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RYTM News Sentiment▼0.591.00▲Average Medical News Sentiment RYTM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RYTM Articles This Week▼357▲RYTM Articles Average Week Remove Ads Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Summit Therapeutics News Today Genmab A/S News Today Dr. Reddy's Laboratories News Today Moderna News Today Viatris News Today Qiagen News Today Ascendis Pharma A/S News Today Roivant Sciences News Today Lantheus News Today TG Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RYTM) was last updated on 4/14/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredThe rotation into gold miners is on.They’re deeply undervalued gold developers with massive in-the-ground, proven resources - and now, fast-track ...Golden Portfolio | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
